Silo Pharma (NASDAQ: SILO) announced that its board of directors authorized a share repurchase program to acquire up to $1 million of the company’s common stock. Purchases may occur on the open market, through privately negotiated transactions or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements. The company reported 13,318,273 shares of common stock outstanding as of Nov. 13, 2025, according to its quarterly report for the period ended Sept. 30, 2025. The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations, and the program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion.
To view the full press release, visit https://ibn.fm/gU3uZ
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com
MissionIR is powered by IBN
